{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T19:31:47Z","timestamp":1777059107983,"version":"3.51.4"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.lfs.2024.123228","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T10:02:01Z","timestamp":1731146521000},"page":"123228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Transcription factor PRRX1-activated ANXA6 facilitates EGFR-PKC\u03b1 complex formation and enhances cisplatin sensitivity in bladder cancer"],"prefix":"10.1016","volume":"359","author":[{"given":"Jinlong","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jirong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinpeng","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanhui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoran","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.lfs.2024.123228_bb0005","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.lfs.2024.123228_bb0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2023 Guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.lfs.2024.123228_bb0015","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.euf.2019.10.017","article-title":"Neoadjuvant Therapies for Bladder Cancer in Cisplatin-ineligible Patients: What Options Do We Have?","volume":"6","author":"Basu","year":"2020","journal-title":"Eur Urol Focus"},{"issue":"19","key":"10.1016\/j.lfs.2024.123228_bb0020","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder Cancer: A Review","volume":"324","author":"Lenis","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.lfs.2024.123228_bb0025","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jconrel.2024.04.020","article-title":"Nanodrugs based on co-delivery strategies to combat cisplatin resistance","volume":"370","author":"Wang","year":"2024","journal-title":"J. Control. Release"},{"issue":"15","key":"10.1016\/j.lfs.2024.123228_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22158199","article-title":"Targeting DNA Damage Response and Repair to Enhance Therapeutic Index in Cisplatin-Based Cancer Treatment","volume":"22","author":"Kiss","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.lfs.2024.123228_bb0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.3109\/10408441003601836","article-title":"The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin","volume":"40","author":"Brozovic","year":"2010","journal-title":"Crit. Rev. Toxicol."},{"issue":"6","key":"10.1016\/j.lfs.2024.123228_bb0040","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s00210-022-02227-1","article-title":"The renoprotective effects of gallic acid on cisplatin-induced nephrotoxicity through anti-apoptosis, anti-inflammatory effects, and downregulation of lncRNA TUG1","volume":"395","author":"Amini","year":"2022","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"issue":"3","key":"10.1016\/j.lfs.2024.123228_bb0045","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00441-024-03902-w","article-title":"Combined effect of naringin and adipose tissue-derived mesenchymal stem cell on cisplatin nephrotoxicity through Sirtuin1\/Nrf-2\/HO-1 signaling pathway: a promising nephroprotective candidate","volume":"397","author":"Amini","year":"2024","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.lfs.2024.123228_bb0050","article-title":"Cisplatin in cancer treatment","volume":"206","author":"Romani AMP","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"16","key":"10.1016\/j.lfs.2024.123228_bb0055","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168885","article-title":"Molecular Mechanisms of Chemoresistance Induced by Cisplatin in NSCLC Cancer Therapy","volume":"22","author":"Kryczka","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.lfs.2024.123228_bb0060","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2007.02.001","article-title":"Mechanisms of resistance to cisplatin and carboplatin","volume":"63","author":"Stewart","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.lfs.2024.123228_bb0065","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.22452","article-title":"LncRNA MST1P2\/miR-133b axis affects the chemoresistance of bladder cancer to cisplatin-based therapy via Sirt 1\/p53 signaling","volume":"34","author":"Chen","year":"2020","journal-title":"J. Biochem. Mol. Toxicol."},{"issue":"18","key":"10.1016\/j.lfs.2024.123228_bb0070","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1158\/1078-0432.CCR-24-0724","article-title":"Platinum-Based Chemotherapy Induces Opposing Effects on Immunotherapy Response-Related Spatial and Stromal Biomarkers in the Bladder Cancer Microenvironment","volume":"30","author":"Chelushkin","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lfs.2024.123228_bb0075","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8887437","article-title":"Hypoxia-Induced Autophagy Enhances Cisplatin Resistance in Human Bladder Cancer Cells by Targeting Hypoxia-Inducible Factor-1\u03b1","volume":"2021","author":"Mao","year":"2021","journal-title":"J Immunol Res"},{"issue":"1","key":"10.1016\/j.lfs.2024.123228_bb0080","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-020-01613-y","article-title":"HIF-1\u03b1-dependent miR-424 induction confers cisplatin resistance on bladder cancer cells through down-regulation of pro-apoptotic UNC5B and SIRT4","volume":"39","author":"Yu","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.lfs.2024.123228_bb0085","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-023-03243-5","article-title":"LASS2 enhances chemosensitivity to cisplatin by inhibiting PP2A-mediated \u03b2-catenin dephosphorylation in a subset of stem-like bladder cancer cells","volume":"22","author":"Shi","year":"2024","journal-title":"BMC Med."},{"issue":"13","key":"10.1016\/j.lfs.2024.123228_bb0090","article-title":"Linking Late Endosomal Cholesterol with Cancer Progression and Anticancer Drug Resistance","volume":"23","author":"MKL","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.lfs.2024.123228_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19051444","article-title":"Annexins-Coordinators of Cholesterol Homeostasis in Endocytic Pathways","volume":"19","author":"Rentero","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.lfs.2024.123228_bb0100","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.bbamcr.2016.10.017","article-title":"Annexin A6 in the liver: From the endocytic compartment to cellular physiology","volume":"1864","author":"Enrich","year":"2017","journal-title":"Biochim. Biophys. Acta, Mol. Cell Res."},{"issue":"7","key":"10.1016\/j.lfs.2024.123228_bb0105","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-021-03963-7","article-title":"Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer","volume":"12","author":"Li","year":"2021","journal-title":"Cell Death Dis."},{"issue":"19","key":"10.1016\/j.lfs.2024.123228_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/cells11193007","article-title":"Hypoxia-Inducible Expression of Annexin A6 Enhances the Resistance of Triple-Negative Breast Cancer Cells to EGFR and AR Antagonists","volume":"11","author":"Williams","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.lfs.2024.123228_bb0115","article-title":"ANXA6 Contributes to Radioresistance by Promoting Autophagy via Inhibiting the PI3K\/AKT\/mTOR Signaling Pathway in Nasopharyngeal Carcinoma","volume":"8","author":"Chen","year":"2020","journal-title":"Front Cell Dev Biol."},{"key":"10.1016\/j.lfs.2024.123228_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114536","article-title":"FGFR3 phosphorylates EGFR to promote cisplatin-resistance in ovarian cancer","volume":"190","author":"Zhao","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.lfs.2024.123228_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.archoralbio.2023.105697","article-title":"Tumour microenvironment and aberrant signaling pathways in cisplatin resistance and strategies to overcome in oral cancer","volume":"151","author":"Biswal","year":"2023","journal-title":"Arch. Oral Biol."},{"issue":"7","key":"10.1016\/j.lfs.2024.123228_bb0130","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00432-020-03228-4","article-title":"Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells","volume":"146","author":"Li","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lfs.2024.123228_bb0135","doi-asserted-by":"crossref","DOI":"10.3390\/cancers9050052","article-title":"Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.lfs.2024.123228_bb0140","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.gene.2019.02.076","article-title":"The relation between PI3K\/AKT signalling pathway and cancer","volume":"698","author":"Noorolyai","year":"2019","journal-title":"Gene"},{"issue":"6","key":"10.1016\/j.lfs.2024.123228_bb0145","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0092-8674(00)80595-4","article-title":"Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor","volume":"96","author":"Brunet","year":"1999","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.lfs.2024.123228_bb0150","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1038\/onc.2012.303","article-title":"Annexin A6 is a scaffold for PKC\u03b1 to promote EGFR inactivation","volume":"32","author":"Koese","year":"2013","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.lfs.2024.123228_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/biom10091288","article-title":"Activated Protein Kinase C (PKC) Is Persistently Trafficked with Epidermal Growth Factor (EGF) Receptor","volume":"10","author":"Heckman","year":"2020","journal-title":"Biomolecules"},{"issue":"9","key":"10.1016\/j.lfs.2024.123228_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107468","article-title":"pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels","volume":"9","author":"Geeleher","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.lfs.2024.123228_bb0165","doi-asserted-by":"crossref","unstructured":"Sherman BT, Hao M, Qiu J, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022; 50(W1):W216-w221. doi:https:\/\/doi.org\/10.1093\/nar\/gkac194.","DOI":"10.1093\/nar\/gkac194"},{"issue":"14","key":"10.1016\/j.lfs.2024.123228_bb0170","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1158\/0008-5472.CAN-12-1370","article-title":"CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set","volume":"72","author":"Reinhold","year":"2012","journal-title":"Cancer Res."},{"issue":"7580","key":"10.1016\/j.lfs.2024.123228_bb0175","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nature15736","article-title":"Pharmacogenomic agreement between two cancer cell line data sets","volume":"528","author":"Nicolas Stransky","year":"2015","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.lfs.2024.123228_bb0180","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","article-title":"A Landscape of Pharmacogenomic Interactions in Cancer","volume":"166","author":"Iorio","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.lfs.2024.123228_bb0185","doi-asserted-by":"crossref","unstructured":"Guo S, Xu Z, Dong X, et al. GPSAdb: a comprehensive web resource for interactive exploration of genetic perturbation RNA-seq datasets. Nucleic Acids Res.. 2023; 51(D1):D964-d968. doi:https:\/\/doi.org\/10.1093\/nar\/gkac1066.","DOI":"10.1093\/nar\/gkac1066"},{"issue":"2","key":"10.1016\/j.lfs.2024.123228_bb0190","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40484-013-0012-4","article-title":"Modeling the specificity of protein-DNA interactions","volume":"1","author":"Stormo","year":"2013","journal-title":"Quant Biol."},{"key":"10.1016\/j.lfs.2024.123228_bb0195","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.freeradbiomed.2023.09.017","article-title":"CAB39 promotes cisplatin resistance in bladder cancer via the LKB1-AMPK-LC3 pathway","volume":"208","author":"Gao","year":"2023","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.lfs.2024.123228_bb0200","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-023-01217-x","article-title":"SUMOylation of AnxA6 facilitates EGFR-PKC\u03b1 complex formation to suppress epithelial cancer growth","volume":"21","author":"Sheng","year":"2023","journal-title":"Cell Commun Signal"},{"issue":"2","key":"10.1016\/j.lfs.2024.123228_bb0205","first-page":"396","article-title":"The role of PRRX1 in the apoptosis of A549 cells induced by cisplatin","volume":"9","author":"Zhu","year":"2017","journal-title":"Am. J. Transl. Res."},{"issue":"3","key":"10.1016\/j.lfs.2024.123228_bb0210","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.lfs.2024.123228_bb0215","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.euo.2023.11.022","article-title":"PrECOG PrE0807: A Phase 1b Feasibility Trial of Neoadjuvant Nivolumab Without and with Lirilumab in Patients with Muscle-invasive Bladder Cancer Ineligible for or Refusing Cisplatin-based Neoadjuvant Chemotherapy","volume":"7","author":"Grivas","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.lfs.2024.123228_bb0220","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.718721","article-title":"Breast Cancer Stem Cell-Derived ANXA6-Containing Exosomes Sustain Paclitaxel Resistance and Cancer Aggressiveness in Breast Cancer","volume":"9","author":"Guo","year":"2021","journal-title":"Frontiers in cell and developmental biology"},{"issue":"8","key":"10.1016\/j.lfs.2024.123228_bb0225","doi-asserted-by":"crossref","DOI":"10.3390\/cells9081855","article-title":"Diverse Roles of Annexin A6 in Triple-Negative Breast Cancer Diagnosis, Prognosis and EGFR-Targeted Therapies","volume":"9","author":"Korolkova","year":"2020","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.lfs.2024.123228_bb0230","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/0008-5472.CAN-10-2384","article-title":"EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment","volume":"71","author":"Liccardi","year":"2011","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.lfs.2024.123228_bb0235","first-page":"2958","article-title":"A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor","volume":"7","author":"Ciardiello","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.lfs.2024.123228_bb0240","article-title":"ANXA6: a key molecular player in cancer progression and drug resistance","volume":"14","author":"Cao","year":"2023","journal-title":"Discov. Oncol."},{"issue":"1","key":"10.1016\/j.lfs.2024.123228_bb0245","first-page":"123","article-title":"Association of p120 ras GAP with endocytic components and colocalization with epidermal growth factor (EGF) receptor in response to EGF stimulation","volume":"7","author":"Wang","year":"1996","journal-title":"Cell Growth Differ."},{"issue":"1","key":"10.1016\/j.lfs.2024.123228_bb0250","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3892\/ijo.2013.1918","article-title":"Prx1 modulates the chemosensitivity of lung cancer to docetaxel through suppression of FOXO1-induced apoptosis","volume":"43","author":"Hwang","year":"2013","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.lfs.2024.123228_bb0255","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-024-01573-2","article-title":"SUMOylation of annexin A6 retards cell migration and tumor growth by suppressing RHOU\/AKT1-involved EMT in hepatocellular carcinoma","volume":"22","author":"Yang","year":"2024","journal-title":"Cell Commun Signal"},{"issue":"6","key":"10.1016\/j.lfs.2024.123228_bb0260","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ccr.2012.10.012","article-title":"Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1","volume":"22","author":"Oca\u00f1a","year":"2012","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.lfs.2024.123228_bb0265","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/bjc.2013.339","article-title":"Paired related homoeobox 1, a new EMT inducer, is involved in metastasis and poor prognosis in colorectal cancer","volume":"109","author":"Takahashi","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"745","key":"10.1016\/j.lfs.2024.123228_bb0270","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.abg8191","article-title":"CD9 mediates the uptake of extracellular vesicles from cancer-associated fibroblasts that promote pancreatic cancer cell aggressiveness","volume":"15","author":"Nigri","year":"2022","journal-title":"Sci. Signal."},{"issue":"6","key":"10.1016\/j.lfs.2024.123228_bb0275","doi-asserted-by":"crossref","DOI":"10.1111\/boc.202200110","article-title":"Annexin-A5 and annexin-A6 silencing prevents metastasis of breast cancer cells in zebrafish","volume":"115","author":"Gounou","year":"2023","journal-title":"Biol. Cell."},{"issue":"8","key":"10.1016\/j.lfs.2024.123228_bb0280","first-page":"3892","article-title":"Prrx1 promotes resistance to temozolomide by upregulating ABCC1 and inducing vasculogenic mimicry in glioma","volume":"12","author":"Chen","year":"2022","journal-title":"Am. J. Cancer Res."},{"issue":"4","key":"10.1016\/j.lfs.2024.123228_bb0285","first-page":"3183","article-title":"Paired-related homeobox 1 overexpression promotes multidrug resistance via PTEN\/PI3K\/AKT signaling in MCF-7 breast cancer cells","volume":"22","author":"Luo","year":"2020","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.lfs.2024.123228_bb0290","doi-asserted-by":"crossref","unstructured":"Zhu M, Ye C, Wang J, et al. Activation of COL11A1 by PRRX1 promotes tumor progression and radioresistance in ovarian cancer. Int. J. Radiat. Biol. 2021; 97(7):958\u2013967. doi:https:\/\/doi.org\/10.1080\/09553002.2021.1928780.","DOI":"10.1080\/09553002.2021.1928780"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002432052400818X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002432052400818X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T12:05:44Z","timestamp":1738152344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002432052400818X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":58,"alternative-id":["S002432052400818X"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2024.123228","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transcription factor PRRX1-activated ANXA6 facilitates EGFR-PKC\u03b1 complex formation and enhances cisplatin sensitivity in bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2024.123228","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"123228"}}